Status:

TERMINATED

PredictEndTB Signature for Individualizing Treatment in Multidrug-Resistant Tuberculosis

Lead Sponsor:

Research Center Borstel

Collaborating Sponsors:

Ludwig-Maximilians - University of Munich

Conditions:

Tuberculosis, Pulmonary

Tuberculosis, Multidrug-Resistant

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

PredictEndTB signature is a non-inferiority, prospective, parallel-group open-label randomized controlled trial evaluating the efficacy of individualised antituberculous treatment durations that utili...

Detailed Description

This study is a non-inferiority, prospective, parallel-group open-label randomized controlled trial. Three hundred forty-two HIV-negative patients diagnosed with pulmonary tuberculosis (TB) and starti...

Eligibility Criteria

Inclusion

  • Patient starting an MDR-TB treatment or within the first 4 weeks after treatment initiation and before culture conversion.
  • Rifampicin resistant M. tuberculosis detected in sputum using a nucleic acid amplification test.
  • New case of TB or re-treatment.
  • Can give informed consent at the point of recruitment.
  • Contactable (residing in the area covered by participating TB centres and possessing a landline or a mobile phone).
  • Willing to participate for the entire course of the treatment and extensive follow-up.

Exclusion

  • Age \<18 years old.
  • Anti-MDR-TB therapy within 6 months prior to the start date of the current treatment cycle.
  • HIV infection.
  • Non-adherent patient with frequent interruptions.
  • Patient in custodianship or guardianship.
  • Late exclusion criterion: no positive cultures at inclusion and within the first 3 months of treatment.

Key Trial Info

Start Date :

April 1 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2022

Estimated Enrollment :

4 Patients enrolled

Trial Details

Trial ID

NCT04783727

Start Date

April 1 2021

End Date

November 1 2022

Last Update

December 13 2023

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Research Center Borstel

Borstel, Schleswig-Holstein, Germany, 23845

2

Phthisiopneumology Institute Chiril Draganiuc

Chisinau, Moldova, 2025

3

Marius Nasta Pulmonology Institute

Bucharest, Romania

4

Kharkiv National Medical University

Kharkiv, Ukraine, 61000

PredictEndTB Signature for Individualizing Treatment in Multidrug-Resistant Tuberculosis | DecenTrialz